Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission (AML_AlloHCT)

A

Asan Medical Center

Status

Unknown

Conditions

Acute Myeloid Leukemia

Treatments

Procedure: allogeneic hematopoietic cell transplantation

Study type

Observational

Funder types

Other

Identifiers

NCT03337568
2017-0204

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of various clinical variables including HLA-disparity and NK cell-related variables, upon outcomes of allogeneic hematopoietic cell transplantation (HCT) using uniform conditioning regimen including busulfan, fludarabine, and antithymocyte globulin (ATG) in patients with acute myeloid leukemia (AML) in the first complete remission (CR). The donors for allogeneic HCT include HLA-matched siblings, matched unrelated donors, and haploidentical family donors. Therefore, the endpoints of the study are engraftment, secondary graft failure, acute and chronic graft-versus-host disease (GVHD), immune recovery, infections, leukemia recurrence, non-relapse mortality, and relapse-free (RFS) and overall survival (OS) of patients.

Enrollment

110 estimated patients

Sex

All

Ages

16 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Patients with non-promyelocytic AML (intermediate-risk or high-risk diseases by NCCN guideline 2016) in the first CR
  • Patients should be 16 years of age or more and 75 years of age or less
  • The performance status of the patients should be 70 or over by Karnofsky performance scale
  • Patients should have adequate hepatic function (bilirubin less than 2.0 mg/dl, AST less than three times the upper normal limit)
  • Patients should have adequate renal function (creatinine less than 2.0 mg/dl)
  • Patients should have adequate cardiac function (ejection fraction > 40% on MUGA scan)
  • Patients and stem cell donors must sign informed consent
  • For hematopoietic cell donor, if a patient has an HLA-matched sibling (65 years or younger), that sibling will be a cell donor. If a patient does not have an HLA-matched sibling but an HLA-A, B, C, DRB1 7-8/8 matched unrelated donor, the unrelated donor will be a cell donor. If a patient has neither HLA-matched sibling nor unrelated donor, an HLA-haploidentical familial donor will be a cell donor.

Trial contacts and locations

0

Loading...

Central trial contact

Seunghyun Baek, RN; Kyoo-Hyung Lee, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems